No products in the cart.
Pamidronate Disodium Injection
$1.00
High-purity Pamidronate Disodium 15mg injectable solution, 10 vials per box. Manufactured by Chengdu Tiantai Shan Pharmaceutical Co., Ltd., it’s a nitrogen-containing bisphosphonate ideal for bone metabolism, osteoporosis, and oncology research.
Description
Pamidronate Disodium Injection Description
Product name: Pamidronate disodium for injection
Packing specification: 15mg*10 bottles Product dosage form: injection ? Packing unit: box
Approval number: National medicine standard H20093151 Drug standard code: 86902066001833
Manufacturer: Chengdu Tiantaishan Pharmaceutical Co., Ltd.
Pamidronate Disodium (pamidronic acid) is a second-generation nitrogen-containing bisphosphonate clinically used to prevent bone loss, treat osteoporosis, Paget’s disease, hypercalcemia of malignancy, and multiple myeloma-related bone disease?patents.google.com+12en.wikipedia.org+12prospectresearchreports.com+12.
This injection contains 15mg of active compound per vial, intended for intravenous infusion in research settings exploring:
Bone resorption and metabolism
Neoplastic bone lesions
Calcium homeostasis
Bisphosphonate-related side effects such as osteonecrosis of the jaw and hypocalcemia
Clinical pharmacokinetics show protein-binding ~54%, renal elimination, and a long half-life (~28±7h), making it suitable for steady-state dosing and mechanistic studies en.wikipedia.org.
Product Specifications
| Feature | Details |
|---|---|
| Product Name | Pamidronate Disodium Injection |
| Strength | 15mg pamidronate per vial |
| Quantity | 10 vials per box |
| Formulation | Sterile aqueous solution for IV infusion |
| Manufacturer | Chengdu Tiantai Shan Pharmaceutical Co., Ltd. |
| Approval Number (NMPA) | H20093151 |
| Product Code | 86902066001833 |
| Storage | Store at 2–8°C; protect from freeze and light |
| Shelf Life | 24 months (as per packaging) |
| Appearance | Clear, colorless solution |
| Administration Route | Intravenous infusion after dilution |
| Pharmacokinetics | Protein bound 54%, renal excretion, elimination half-life ~28h |
Mechanism of Action & Key Benefits
Bone preservation: Inhibits osteoclast-mediated bone resorption, reducing skeletal-related events.
Clinical relevance: Doses of 30–90mg monthly empower research in osteolytic conditions and hypercalcemia studies.
Rich pharmacokinetics: High protein binding and renal clearance favor predictable blood levels in models.
Side effect profiling: Common adverse reactions include fever, bone pain, hypocalcemia, and gastrointestinal upset—valuable for mechanistic toxicity research.
Why Choose This Product?
Approved and traceable by NMPA
Pharma-grade single-dose vials for convenient use
Supports robust research in bone disease, oncology, and metabolism
Ideal for chronic dosing or pharmacokinetic investigations
Zoledronic Acid Injection (Bisphosphonate)
Alendronate Sodium for Injection
Denosumab for Injection (RANKL Inhibitor)
Summary
Pamidronate Disodium 15mg Injection by Chengdu Tiantai Shan Pharma is a reliable research-grade tool for bone metabolism, oncology, and calcium homeostasis studies. With high-quality manufacture, clear pharmacokinetic profile, and injectable format, it’s suitable for a variety of lab models.
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 25 × 23 × 25 cm |
1 review for Pamidronate Disodium Injection
Related products
Reduced Glutathione Injection
Ruiyang Reduced Glutathione Injection (0.6g per vial × 10) by Ruiyang Pharmaceutical Co., Ltd. Ideal for antioxidant, detoxification, and hepatic-protection research in metabolic and oxidative stress studies. $2.00Limertinib Tablets
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M mutated non small cell lung cancer, including patients with brain metastases. $1.00Propranolol Hydrochloride Oral Solution
Propranolol Hydrochloride Oral Solution (HeMeiJia) offers a sweet strawberry-mint 40mg/5mL formulation in a 40mL bottle. Approved by NMPA under H20213549, this solution provides accurate dosing—ideal for infantile hemangioma, pediatric cardiovascular, or pharmacokinetic studies.
$1.00Elranatamab Injection
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76mg/1.9mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug 2023) and EMA (Dec 2023). Ideal for oncology, immunotherapy, and Tcell engager studies.
$1.00
mamr –
Not bad, thank you